chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: caught COVID and tested positive on 18-Dec 2023. Her symptoms are reminiscent of a head cold, including sniffling/sneezing as well as chills and fatigue; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (caught COVID and tested positive on 18-Dec 2023. Her symptoms are reminiscent of a head cold, including sniffling/sneezing as well as chills and fatigue) in a female patient of an unknown age who received mRNA-1273.815 (SPIKEVAX 2023-2024) (batch no. A45552B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 07-Oct-2023, the patient received fourth dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (Intramuscular use) 1 dosage form. On 17-Dec-2023,  after starting mRNA-1273.815 (SPIKEVAX 2023-2024), the patient experienced COVID-19 (caught COVID and tested positive on 18-Dec 2023. Her symptoms are reminiscent of a head cold, including sniffling/sneezing as well as chills and fatigue). At the time of the report, COVID-19 (caught COVID and tested positive on 18-Dec 2023. Her symptoms are reminiscent of a head cold, including sniffling/sneezing as well as chills and fatigue) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 18-Dec-2023, SARS-CoV-2 test: (Positive) Nasal Swab.         No relevant medical history and concurrent conditions were reported. Prior to vaccination, the patient was not diagnosed with COVID-19.  The patient had not received any other vaccines within 4 weeks prior to the COVID vaccine. The patient had not received any other medications within 2 weeks of vaccination. No treatment was received.
Sex: F
Vaccine: COVID19-2
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: Her only symptom is post-nasal drip. However a home test kit tested her positive for COVID-19.; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Her only symptom is post-nasal drip. However a home test kit tested her positive for COVID-19.) in a female patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     Concurrent medical conditions included Blood pressure high. Concomitant products included NIFEDIPINE for an unknown indication.    On 30-Sep-2023, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular use) 1 dosage form. On 19-Dec-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced COVID-19 (Her only symptom is post-nasal drip. However a home test kit tested her positive for COVID-19.). At the time of the report, COVID-19 (Her only symptom is post-nasal drip. However a home test kit tested her positive for COVID-19.) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 19-Dec-2023, SARS-CoV-2 test: (Positive) Nasal Swab.         Treatment information was not provided.
Sex: U
Vaccine: COVID19
Symptoms: COVID-19
Clinical narrative: I came down with Covid 12/9/23; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (I came down with Covid 12/9/23) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (batch no. 205e23a) for COVID-19 prophylaxis.     No Medical History information was reported.    On 27-Sep-2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (unknown route) 1 dosage form. On 09-Dec-2023,  after starting mRNA-1273.815 (SPIKEVAX 2023-2024 PFS), the patient experienced COVID-19 (I came down with Covid 12/9/23). At the time of the report, COVID-19 (I came down with Covid 12/9/23) had not resolved.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (Unknown) was unknown.   For mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported.  Prior to that date patient had received all Moderna covid vaccines and boosters as they became available.  No treatment information was reported.   Most recent FOLLOW-UP information incorporated above includes: On 22-Dec-2023: Live follow-up received: Reference ids updated.
Age: 60.0
Sex: F
Vaccine: COVID19, RVX
Symptoms: Injection site erythema, Injection site scar
Clinical narrative: The pharmacist states that it looks like Keloids; About 2 weeks ago while showering the patient noticed redness on the Spikevax injection site on the left arm; This spontaneous case was reported by a pharmacist and describes the occurrence of INJECTION SITE SCAR (The pharmacist states that it looks like Keloids) and INJECTION SITE ERYTHEMA (About 2 weeks ago while showering the patient noticed redness on the Spikevax injection site on the left arm) in a 60-year-old female patient who received mRNA-1273.815 (SPIKEVAX 2023-2024) (batch no. 8058492) for COVID-19 prophylaxis.    Co-suspect product included non-company product RSV VACCINE for an unknown indication.    The patient's past medical history included Keloid scar (Keloid scar after surgery in the past (Date Unknown).) and Surgery (Keloid scar after surgery in the past (Date Unknown)). Concomitant products included INFLUENZA VACCINE for an unknown indication.   On 28-Oct-2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form and dose of RSV VACCINE (unknown route) 1 dosage form. In December 2023, the patient experienced INJECTION SITE SCAR (The pharmacist states that it looks like Keloids) and INJECTION SITE ERYTHEMA (About 2 weeks ago while showering the patient noticed redness on the Spikevax injection site on the left arm). At the time of the report, INJECTION SITE SCAR (The pharmacist states that it looks like Keloids) and INJECTION SITE ERYTHEMA (About 2 weeks ago while showering the patient noticed redness on the Spikevax injection site on the left arm) outcome was unknown.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.   For mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown), the reporter did not provide any causality assessments.   Patient receives other vaccines in the 4 weeks prior to COVID-19 vaccine.  Patient receives RSV Arexvy in the left arm 1 inch below the Spikevax injection site.  Suspect vaccine dosage text was reported as unknown. Expiry date of the vaccine was 31-Mar-2024.  It was reported that About 2 weeks ago while showering the patient noticed redness on the Spikevax injection site on the left arm. She came back and showed it to the pharmacist on 22-Dec-2023. The pharmacist states that it looks like Keloids. The patient told the pharmacist that she had Keloid scars after a surgery in the past. The patient had an appointment with the dermatologist this week.  Treatment information was not provided.
Sex: U
Vaccine: FLUX
Symptoms: Nasopharyngitis, Pyrexia
Clinical narrative: fever; slight cold; Initial information received on 15-Dec-2023 regarding an unsolicited valid Social Media non-serious case received via patient.  This case involves an unknown age and unknown gender patient who had fever and slight cold while receiving influenza vaccine.  The patient's past medical history, medical treatment(s), vaccination(s), concomitant(s) and family history were not provided.   On an unknown date, the patient received an unknown dose of suspect influenza vaccine produced by unknown manufacturer (strength, form, expiry date, batch number: unknown) not reported via unknown route in unknown administration site for prophylactic vaccination (immunization).  On an unknown date the patient had events of fever (pyrexia) and slight cold (nasopharyngitis) (unknown latency) following the administration of influenza vaccine.  It was reported, there is practically no one who has had severe side effects (in any case there may be a small number for all the vaccines that have existed since Pasteur). All the people around me have been vaccinated (I have about a hundred people around me, more or less personally, in my various activities: tennis, language classes, associations, friends), and no serious effects. Just mild effects like mine, fever, etc. not much at all. On the other hand, none have been seriously ill. At worst just a slight cold when they contracted Covid (a variant). In contrast, I have two unvaccinated friends who died from covid  It was unknown if any lab data/test results available.  Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the events.  Outcome: Unknown for the events.
Sex: F
Vaccine: YF
Symptoms: Incorrect route of product administration, No adverse event
Clinical narrative: accidentally administered YF-VAX intramuscularly instead of subcutaneously with no reported adverse event; Initial information received on 19-Dec-2023 regarding an unsolicited valid non-serious case received from a Pharmacist.  This case involves an unknown age female patient who accidentally administered YELLOW FEVER VACCINE [YF-VAX] intramuscularly instead of subcutaneously with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect yellow fever vaccine - Solution for injection (lot- UJ966AA and UJ819AA, expiration date- 01-May-2025 and 18-Apr-2024) via intramuscular route in unknown administration site (dose, strength: not provided) for Immunisation (incorrect route of product administration) (latency- same day).  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Sex: M
Vaccine: YF
Symptoms: Incorrect route of product administration, No adverse event
Clinical narrative: accidentally administered YF-VAX to patient intramuscularly instead of subcutaneously with no reported adverse event; Initial information received from Regulatory Authority on 19-Dec-2023 regarding an unsolicited valid non-serious case received from a Pharmacist.  This case is linked to case 2023SA396932 (RA).  This case involves an unknown age male patient who accidentally administered YELLOW FEVER VACCINE - US [YF-VAX] to patient intramuscularly instead of subcutaneously with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect yellow fever vaccine - RA Solution for injection (lot- UJ966AA and expiration date- 05-Jan -2025) via intramuscular route in unknown administration site (dose, strength: not provided) for Immunisation (incorrect route of product administration) (latency- same day).  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 74.0
Sex: U
Vaccine: COVID19
Symptoms: Malaise, Pain in extremity
Clinical narrative: I did not feel well; My arm was sore for two or three days; This spontaneous case was reported by a non-healthcare professional and describes the occurrence of MALAISE (I did not feel well) and PAIN IN EXTREMITY (My arm was sore for two or three days) in a 74-year-old patient of an unknown gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     The patient's past medical history included COVID-19 (The patient got hit with covid in Nov-2020 before the vaccine was available. It was awful and I was out of work for 7 weeks) in November 2020. Previously administered products included for Product used for unknown indication: Pfizer (Patient assumed they gave Pfizer which she has always gotten before). Past adverse reactions to the above products included No adverse event with Pfizer.    In October 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In 2023, the patient experienced MALAISE (I did not feel well) and PAIN IN EXTREMITY (My arm was sore for two or three days). At the time of the report, MALAISE (I did not feel well) and PAIN IN EXTREMITY (My arm was sore for two or three days) outcome was unknown.            Concomitant product use was not provided by the reporter.  The patient received vaccine in Oct but when patient went home realized received Spikevax which patient did not really want. Patient assumed they would give the Pfizer which patient have always gotten before. They never asked patient but then they may have been out of the Pfizer. The patient did not feel well, and arm was sore for two or three days. The patient hopes the one got was as good as the Pfizer.  Treatment information was not provided.
Age: 80.0
Sex: M
Vaccine: RSV
Symptoms: Arthralgia, Hypoaesthesia, Myalgia, Pain in extremity, Paraesthesia
Clinical narrative: 10 day after receiving Arexvy vaccination I began to experience bi-lateral arthralgia & myalgia in my upper extremities (shoulders and elbows) with mild pain, tingling and numbness in both hands & wrists. These symptoms often awaken me at night.
Age: 80.0
Sex: M
Vaccine: RSV
Symptoms: Sleep disorder
Clinical narrative: 10 day after receiving Arexvy vaccination I began to experience bi-lateral arthralgia & myalgia in my upper extremities (shoulders and elbows) with mild pain, tingling and numbness in both hands & wrists. These symptoms often awaken me at night.
Age: 10.0
Sex: M
Vaccine: COVID19
Symptoms: Extra dose administered
Clinical narrative: 10yo pt received a 4th dose of Pfizer 6months -4 years 3mcg covid vaccine on 12/14/2023
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Autoimmune disorder
Clinical narrative: Received Pfizer comirnaty and developed an autoimmune condition
Sex: U
Vaccine: TD
Symptoms: Asthenia, Hypotension, Pyrexia, Tachycardia
Clinical narrative: tachycardia, generalized weakness, fever, hypotension
Age: 55.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site cellulitis, Injection site induration, Injection site pain, Injection site warmth
Clinical narrative: Received the Shingrix vaccine Tuesday, 19Dec2023 and developed cellulitis near the injection site - became continuously hot, hard and painful over the 2 days following the vaccination. Diagnosed on Friday, 22Dec2023 and started antibiotic therapy.
Age: 72.0
Sex: M
Vaccine: RSV
Symptoms: Angioedema, Laryngoscopy abnormal, Lip swelling, Pharyngeal oedema, Swelling face
Clinical narrative: 10002424:ANGIOEDEMA - Patient is a 72 year old with PMH of tobacco use with multiple pulmonary nodules, carpal tunnel syndrome, hyperlipidemia, HTN on lisinopril, lumbar spinal stenosis, choledocholithiasis in spring 2023 s/p ERCP, and chronic sinusitis who presented to the ED with lip and left cheek and jaw swelling after receiving rsv vaccine on 12/6 and on home lisinopril. On the evening of 12/7, patient noted that his left cheek and jaw line had some swelling. He went to bed, and when he woke up the next morning he noticed interval increase in the swelling. He then went to work at his auto body shop where his secretary noticed that his lip was also swelling. She encouraged him to present to the ED, which he did.  In the ED his VS were wnl. He was treated with diphenhydramine 25 mg iv push,  methylprednisolone 125 iv push, and famotidine 20 mg iv push. ENT evaluated the patient and performed laryngoscopy which revealed mild post-cricoid edema. Lisinopril was discontinued upon discharge and RSV vaccine was entered as adr as well as lisinopril. Patient was discharged home on cetirizine, famotidine, and methylprednisolone for the angioedema.
Sex: U
Vaccine: COVID19
Symptoms: Upper respiratory tract infection
Clinical narrative: Patient reports that she had an upper respiratory infection. Patient also mentioned that she just received her Covid vaccine. No additional information given
Age: 89.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19-2
Symptoms: COVID-19, Death, SARS-CoV-2 test positive
Clinical narrative: Pt deceased after contracting COVID-19 virus in December 2023. No boosters administered after Oct 2022 for 4th dose.
Age: 74.0
Sex: M
Vaccine: COVID19-2
Symptoms: Acute respiratory failure, Angiogram pulmonary abnormal, Blood pressure increased, Blood sodium increased, COVID-19
Clinical narrative: Patient  is a 75 y.o. male with history of chronic respiratory failure (supplemental oxygen at nights only), COPD, lung cancer presented to Medical Center with respiratory failure in the setting of COVID-19 infection, possible CAP, and COPD exacerbation.    Acute on chronic respiratory failure with hypoxia and hypercapnia At home uses NC at night 3 L but using during day as well Bipap at bedtime and prn COVID 19, CAP, and COPD exacerbation with decreased exercise tolerance at baseline Pulmonary consulted Weaned back to home NC 3 L 11/12, still hypoxia with exertion but resolves quickly without tachycardia, pt feels back to baseline Suspect this is patient baseline at home          COVID 19 Infection Secondary Community acquired PNA, suspected Date of onset of symptoms: 11/01/23 Symptoms present on admission: SOB, cough, wheezing Date of positive COVID19 test: 11/04/23 Vaccination status: vaccinated Imaging: CTPA on 11/06/23 noted R basilar airspace disease, noted remnants of lung cancer.  O2 needs on admission: 5 L nasal cannula and bipap Medical therapy: remdesivir, steroids, and ceftriaxone/azithromycin changed to Cefdinir/azithromycin Consultants following: Pulmonology consulted Anticipated special isolation end date: 11/11/23     COPD exacerbation Productive cough, wheezing, dyspnea on admit CXR 11/6 negative for acute gross abnormalities.  Afebrile, no leukocytosis Loaded w/ Decadron 10 mg, continued on 6 mg daily Dulera, spiriva, albuterol nebs   Hypernatremia, mild Na 147 11/8, pt with poor po because doesn't like food and will only drink flavored water Encouraged better po intake, family to bring in food/flavor packets, RN obtained crystal light Resolved with better liquid intake Lung cancer LUE and RUL History of B/L lung cancer s/p surgical intervention and radiation.   CTPA showing RUL mass (2.3 x 1.8 cm) with surgical clips CT scan of chest on 09/2023 showing RUL mass measuring 3.4 x 1.9 cm (per report, stable from previous). Follows closely with Oncology at the Facility.   Mild Transaminitis Stable 11/8, monitored with remdesivir   Chronic Pain Verified and resumed home methadone Stable, controlled   Mildly Elevated BP, situational 11/8 in 150s No home medications Outpatient follow up
Age: 74.0
Sex: M
Vaccine: COVID19-2
Symptoms: Chest X-ray normal, Chronic obstructive pulmonary disease, Computerised tomogram thorax abnormal, Condition aggravated, Dyspnoea
Clinical narrative: Patient  is a 75 y.o. male with history of chronic respiratory failure (supplemental oxygen at nights only), COPD, lung cancer presented to Medical Center with respiratory failure in the setting of COVID-19 infection, possible CAP, and COPD exacerbation.    Acute on chronic respiratory failure with hypoxia and hypercapnia At home uses NC at night 3 L but using during day as well Bipap at bedtime and prn COVID 19, CAP, and COPD exacerbation with decreased exercise tolerance at baseline Pulmonary consulted Weaned back to home NC 3 L 11/12, still hypoxia with exertion but resolves quickly without tachycardia, pt feels back to baseline Suspect this is patient baseline at home          COVID 19 Infection Secondary Community acquired PNA, suspected Date of onset of symptoms: 11/01/23 Symptoms present on admission: SOB, cough, wheezing Date of positive COVID19 test: 11/04/23 Vaccination status: vaccinated Imaging: CTPA on 11/06/23 noted R basilar airspace disease, noted remnants of lung cancer.  O2 needs on admission: 5 L nasal cannula and bipap Medical therapy: remdesivir, steroids, and ceftriaxone/azithromycin changed to Cefdinir/azithromycin Consultants following: Pulmonology consulted Anticipated special isolation end date: 11/11/23     COPD exacerbation Productive cough, wheezing, dyspnea on admit CXR 11/6 negative for acute gross abnormalities.  Afebrile, no leukocytosis Loaded w/ Decadron 10 mg, continued on 6 mg daily Dulera, spiriva, albuterol nebs   Hypernatremia, mild Na 147 11/8, pt with poor po because doesn't like food and will only drink flavored water Encouraged better po intake, family to bring in food/flavor packets, RN obtained crystal light Resolved with better liquid intake Lung cancer LUE and RUL History of B/L lung cancer s/p surgical intervention and radiation.   CTPA showing RUL mass (2.3 x 1.8 cm) with surgical clips CT scan of chest on 09/2023 showing RUL mass measuring 3.4 x 1.9 cm (per report, stable from previous). Follows closely with Oncology at the Facility.   Mild Transaminitis Stable 11/8, monitored with remdesivir   Chronic Pain Verified and resumed home methadone Stable, controlled   Mildly Elevated BP, situational 11/8 in 150s No home medications Outpatient follow up
Age: 74.0
Sex: M
Vaccine: COVID19-2
Symptoms: Exercise tolerance decreased, Fluid intake reduced, Hypercapnia, Hypernatraemia, Hypertransaminasaemia
Clinical narrative: Patient  is a 75 y.o. male with history of chronic respiratory failure (supplemental oxygen at nights only), COPD, lung cancer presented to Medical Center with respiratory failure in the setting of COVID-19 infection, possible CAP, and COPD exacerbation.    Acute on chronic respiratory failure with hypoxia and hypercapnia At home uses NC at night 3 L but using during day as well Bipap at bedtime and prn COVID 19, CAP, and COPD exacerbation with decreased exercise tolerance at baseline Pulmonary consulted Weaned back to home NC 3 L 11/12, still hypoxia with exertion but resolves quickly without tachycardia, pt feels back to baseline Suspect this is patient baseline at home          COVID 19 Infection Secondary Community acquired PNA, suspected Date of onset of symptoms: 11/01/23 Symptoms present on admission: SOB, cough, wheezing Date of positive COVID19 test: 11/04/23 Vaccination status: vaccinated Imaging: CTPA on 11/06/23 noted R basilar airspace disease, noted remnants of lung cancer.  O2 needs on admission: 5 L nasal cannula and bipap Medical therapy: remdesivir, steroids, and ceftriaxone/azithromycin changed to Cefdinir/azithromycin Consultants following: Pulmonology consulted Anticipated special isolation end date: 11/11/23     COPD exacerbation Productive cough, wheezing, dyspnea on admit CXR 11/6 negative for acute gross abnormalities.  Afebrile, no leukocytosis Loaded w/ Decadron 10 mg, continued on 6 mg daily Dulera, spiriva, albuterol nebs   Hypernatremia, mild Na 147 11/8, pt with poor po because doesn't like food and will only drink flavored water Encouraged better po intake, family to bring in food/flavor packets, RN obtained crystal light Resolved with better liquid intake Lung cancer LUE and RUL History of B/L lung cancer s/p surgical intervention and radiation.   CTPA showing RUL mass (2.3 x 1.8 cm) with surgical clips CT scan of chest on 09/2023 showing RUL mass measuring 3.4 x 1.9 cm (per report, stable from previous). Follows closely with Oncology at the Facility.   Mild Transaminitis Stable 11/8, monitored with remdesivir   Chronic Pain Verified and resumed home methadone Stable, controlled   Mildly Elevated BP, situational 11/8 in 150s No home medications Outpatient follow up
Age: 74.0
Sex: M
Vaccine: COVID19-2
Symptoms: Hypophagia, Hypoxia, Lung disorder, Lung neoplasm malignant, Pain
Clinical narrative: Patient  is a 75 y.o. male with history of chronic respiratory failure (supplemental oxygen at nights only), COPD, lung cancer presented to Medical Center with respiratory failure in the setting of COVID-19 infection, possible CAP, and COPD exacerbation.    Acute on chronic respiratory failure with hypoxia and hypercapnia At home uses NC at night 3 L but using during day as well Bipap at bedtime and prn COVID 19, CAP, and COPD exacerbation with decreased exercise tolerance at baseline Pulmonary consulted Weaned back to home NC 3 L 11/12, still hypoxia with exertion but resolves quickly without tachycardia, pt feels back to baseline Suspect this is patient baseline at home          COVID 19 Infection Secondary Community acquired PNA, suspected Date of onset of symptoms: 11/01/23 Symptoms present on admission: SOB, cough, wheezing Date of positive COVID19 test: 11/04/23 Vaccination status: vaccinated Imaging: CTPA on 11/06/23 noted R basilar airspace disease, noted remnants of lung cancer.  O2 needs on admission: 5 L nasal cannula and bipap Medical therapy: remdesivir, steroids, and ceftriaxone/azithromycin changed to Cefdinir/azithromycin Consultants following: Pulmonology consulted Anticipated special isolation end date: 11/11/23     COPD exacerbation Productive cough, wheezing, dyspnea on admit CXR 11/6 negative for acute gross abnormalities.  Afebrile, no leukocytosis Loaded w/ Decadron 10 mg, continued on 6 mg daily Dulera, spiriva, albuterol nebs   Hypernatremia, mild Na 147 11/8, pt with poor po because doesn't like food and will only drink flavored water Encouraged better po intake, family to bring in food/flavor packets, RN obtained crystal light Resolved with better liquid intake Lung cancer LUE and RUL History of B/L lung cancer s/p surgical intervention and radiation.   CTPA showing RUL mass (2.3 x 1.8 cm) with surgical clips CT scan of chest on 09/2023 showing RUL mass measuring 3.4 x 1.9 cm (per report, stable from previous). Follows closely with Oncology at the Facility.   Mild Transaminitis Stable 11/8, monitored with remdesivir   Chronic Pain Verified and resumed home methadone Stable, controlled   Mildly Elevated BP, situational 11/8 in 150s No home medications Outpatient follow up
Age: 74.0
Sex: M
Vaccine: COVID19-2
Symptoms: Pneumonia, Positive airway pressure therapy, Productive cough, Pulmonary mass, SARS-CoV-2 test positive
Clinical narrative: Patient  is a 75 y.o. male with history of chronic respiratory failure (supplemental oxygen at nights only), COPD, lung cancer presented to Medical Center with respiratory failure in the setting of COVID-19 infection, possible CAP, and COPD exacerbation.    Acute on chronic respiratory failure with hypoxia and hypercapnia At home uses NC at night 3 L but using during day as well Bipap at bedtime and prn COVID 19, CAP, and COPD exacerbation with decreased exercise tolerance at baseline Pulmonary consulted Weaned back to home NC 3 L 11/12, still hypoxia with exertion but resolves quickly without tachycardia, pt feels back to baseline Suspect this is patient baseline at home          COVID 19 Infection Secondary Community acquired PNA, suspected Date of onset of symptoms: 11/01/23 Symptoms present on admission: SOB, cough, wheezing Date of positive COVID19 test: 11/04/23 Vaccination status: vaccinated Imaging: CTPA on 11/06/23 noted R basilar airspace disease, noted remnants of lung cancer.  O2 needs on admission: 5 L nasal cannula and bipap Medical therapy: remdesivir, steroids, and ceftriaxone/azithromycin changed to Cefdinir/azithromycin Consultants following: Pulmonology consulted Anticipated special isolation end date: 11/11/23     COPD exacerbation Productive cough, wheezing, dyspnea on admit CXR 11/6 negative for acute gross abnormalities.  Afebrile, no leukocytosis Loaded w/ Decadron 10 mg, continued on 6 mg daily Dulera, spiriva, albuterol nebs   Hypernatremia, mild Na 147 11/8, pt with poor po because doesn't like food and will only drink flavored water Encouraged better po intake, family to bring in food/flavor packets, RN obtained crystal light Resolved with better liquid intake Lung cancer LUE and RUL History of B/L lung cancer s/p surgical intervention and radiation.   CTPA showing RUL mass (2.3 x 1.8 cm) with surgical clips CT scan of chest on 09/2023 showing RUL mass measuring 3.4 x 1.9 cm (per report, stable from previous). Follows closely with Oncology at the Facility.   Mild Transaminitis Stable 11/8, monitored with remdesivir   Chronic Pain Verified and resumed home methadone Stable, controlled   Mildly Elevated BP, situational 11/8 in 150s No home medications Outpatient follow up
Age: 74.0
Sex: M
Vaccine: COVID19-2
Symptoms: Wheezing
Clinical narrative: Patient  is a 75 y.o. male with history of chronic respiratory failure (supplemental oxygen at nights only), COPD, lung cancer presented to Medical Center with respiratory failure in the setting of COVID-19 infection, possible CAP, and COPD exacerbation.    Acute on chronic respiratory failure with hypoxia and hypercapnia At home uses NC at night 3 L but using during day as well Bipap at bedtime and prn COVID 19, CAP, and COPD exacerbation with decreased exercise tolerance at baseline Pulmonary consulted Weaned back to home NC 3 L 11/12, still hypoxia with exertion but resolves quickly without tachycardia, pt feels back to baseline Suspect this is patient baseline at home          COVID 19 Infection Secondary Community acquired PNA, suspected Date of onset of symptoms: 11/01/23 Symptoms present on admission: SOB, cough, wheezing Date of positive COVID19 test: 11/04/23 Vaccination status: vaccinated Imaging: CTPA on 11/06/23 noted R basilar airspace disease, noted remnants of lung cancer.  O2 needs on admission: 5 L nasal cannula and bipap Medical therapy: remdesivir, steroids, and ceftriaxone/azithromycin changed to Cefdinir/azithromycin Consultants following: Pulmonology consulted Anticipated special isolation end date: 11/11/23     COPD exacerbation Productive cough, wheezing, dyspnea on admit CXR 11/6 negative for acute gross abnormalities.  Afebrile, no leukocytosis Loaded w/ Decadron 10 mg, continued on 6 mg daily Dulera, spiriva, albuterol nebs   Hypernatremia, mild Na 147 11/8, pt with poor po because doesn't like food and will only drink flavored water Encouraged better po intake, family to bring in food/flavor packets, RN obtained crystal light Resolved with better liquid intake Lung cancer LUE and RUL History of B/L lung cancer s/p surgical intervention and radiation.   CTPA showing RUL mass (2.3 x 1.8 cm) with surgical clips CT scan of chest on 09/2023 showing RUL mass measuring 3.4 x 1.9 cm (per report, stable from previous). Follows closely with Oncology at the Facility.   Mild Transaminitis Stable 11/8, monitored with remdesivir   Chronic Pain Verified and resumed home methadone Stable, controlled   Mildly Elevated BP, situational 11/8 in 150s No home medications Outpatient follow up
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event
Clinical narrative: None stated.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Blood bicarbonate increased, Blood creatinine increased, Blood pH decreased, Brain natriuretic peptide increased
Clinical narrative: Patient is a 77 y.o. male patient of Hospital, with history of chronic respiratory failure typically on 2 L via nasal cannula, paroxysmal atrial fibrillation, coronary artery disease with ischemic cardiomyopathy, baseline left ventricular ejection fraction appears around 30%, COPD, CKD 3, history of CVA, type 2 diabetes, status post ICD who presented to Medical Center with acute on chronic hypoxic and hypercapnic respiratory failure with COVID-pneumonia and COPD exacerbation.   Acute on chronic hypercapnic and hypoxic respiratory failure Secondary to COVID PNA and COPD On 2 L at home and home bipap qhs Most recent VBG pH 7.29, PCO2 65.9, bicarb 31.3 XR chest shows no acute pathology  WBC 4.23, BNP 9054 on admission (baseline between 2K to 9K) BIPAP on admission--weaned successfully down to 3-4 L O2 with bipap at bedtime Dyspnea on exertion flow to improve during stay  Holding further diuresis    COPD exacerbation Resumed dulera plus atrovent/ipratropium, pulm toilet Decadron, doxycyline x 5   COVID-19 PNA COVID + on 11/6/2023 + vaccination Continued Remdesivir, Decadron 6 mg daily  Changed decadron to po 11/8   CAD with ischemic Cardiomyopathy , HFrEF PAF Continued Eliquis, Atorvastatin, Metoprolol, corlanor  LVEF 30% in 2022  Given IV lasix, resume home PO lasix on discharge    CKD III  Cr stable 1.7 , bumped to 2.15  Bumped with IV Lasix DM II noninsulin dependent Diet controlled at home  A1c 11/6 6 Sliding scale insulin while on high dose steroids,  Cont home jardiance
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, COVID-19 pneumonia, Chest X-ray normal, Chronic obstructive pulmonary disease, Condition aggravated
Clinical narrative: Patient is a 77 y.o. male patient of Hospital, with history of chronic respiratory failure typically on 2 L via nasal cannula, paroxysmal atrial fibrillation, coronary artery disease with ischemic cardiomyopathy, baseline left ventricular ejection fraction appears around 30%, COPD, CKD 3, history of CVA, type 2 diabetes, status post ICD who presented to Medical Center with acute on chronic hypoxic and hypercapnic respiratory failure with COVID-pneumonia and COPD exacerbation.   Acute on chronic hypercapnic and hypoxic respiratory failure Secondary to COVID PNA and COPD On 2 L at home and home bipap qhs Most recent VBG pH 7.29, PCO2 65.9, bicarb 31.3 XR chest shows no acute pathology  WBC 4.23, BNP 9054 on admission (baseline between 2K to 9K) BIPAP on admission--weaned successfully down to 3-4 L O2 with bipap at bedtime Dyspnea on exertion flow to improve during stay  Holding further diuresis    COPD exacerbation Resumed dulera plus atrovent/ipratropium, pulm toilet Decadron, doxycyline x 5   COVID-19 PNA COVID + on 11/6/2023 + vaccination Continued Remdesivir, Decadron 6 mg daily  Changed decadron to po 11/8   CAD with ischemic Cardiomyopathy , HFrEF PAF Continued Eliquis, Atorvastatin, Metoprolol, corlanor  LVEF 30% in 2022  Given IV lasix, resume home PO lasix on discharge    CKD III  Cr stable 1.7 , bumped to 2.15  Bumped with IV Lasix DM II noninsulin dependent Diet controlled at home  A1c 11/6 6 Sliding scale insulin while on high dose steroids,  Cont home jardiance
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Diuretic therapy, Dyspnoea exertional, Ejection fraction decreased, Glycosylated haemoglobin normal, Insulin therapy
Clinical narrative: Patient is a 77 y.o. male patient of Hospital, with history of chronic respiratory failure typically on 2 L via nasal cannula, paroxysmal atrial fibrillation, coronary artery disease with ischemic cardiomyopathy, baseline left ventricular ejection fraction appears around 30%, COPD, CKD 3, history of CVA, type 2 diabetes, status post ICD who presented to Medical Center with acute on chronic hypoxic and hypercapnic respiratory failure with COVID-pneumonia and COPD exacerbation.   Acute on chronic hypercapnic and hypoxic respiratory failure Secondary to COVID PNA and COPD On 2 L at home and home bipap qhs Most recent VBG pH 7.29, PCO2 65.9, bicarb 31.3 XR chest shows no acute pathology  WBC 4.23, BNP 9054 on admission (baseline between 2K to 9K) BIPAP on admission--weaned successfully down to 3-4 L O2 with bipap at bedtime Dyspnea on exertion flow to improve during stay  Holding further diuresis    COPD exacerbation Resumed dulera plus atrovent/ipratropium, pulm toilet Decadron, doxycyline x 5   COVID-19 PNA COVID + on 11/6/2023 + vaccination Continued Remdesivir, Decadron 6 mg daily  Changed decadron to po 11/8   CAD with ischemic Cardiomyopathy , HFrEF PAF Continued Eliquis, Atorvastatin, Metoprolol, corlanor  LVEF 30% in 2022  Given IV lasix, resume home PO lasix on discharge    CKD III  Cr stable 1.7 , bumped to 2.15  Bumped with IV Lasix DM II noninsulin dependent Diet controlled at home  A1c 11/6 6 Sliding scale insulin while on high dose steroids,  Cont home jardiance
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: PCO2 increased, Positive airway pressure therapy, Respiratory failure, SARS-CoV-2 test positive, White blood cell count decreased
Clinical narrative: Patient is a 77 y.o. male patient of Hospital, with history of chronic respiratory failure typically on 2 L via nasal cannula, paroxysmal atrial fibrillation, coronary artery disease with ischemic cardiomyopathy, baseline left ventricular ejection fraction appears around 30%, COPD, CKD 3, history of CVA, type 2 diabetes, status post ICD who presented to Medical Center with acute on chronic hypoxic and hypercapnic respiratory failure with COVID-pneumonia and COPD exacerbation.   Acute on chronic hypercapnic and hypoxic respiratory failure Secondary to COVID PNA and COPD On 2 L at home and home bipap qhs Most recent VBG pH 7.29, PCO2 65.9, bicarb 31.3 XR chest shows no acute pathology  WBC 4.23, BNP 9054 on admission (baseline between 2K to 9K) BIPAP on admission--weaned successfully down to 3-4 L O2 with bipap at bedtime Dyspnea on exertion flow to improve during stay  Holding further diuresis    COPD exacerbation Resumed dulera plus atrovent/ipratropium, pulm toilet Decadron, doxycyline x 5   COVID-19 PNA COVID + on 11/6/2023 + vaccination Continued Remdesivir, Decadron 6 mg daily  Changed decadron to po 11/8   CAD with ischemic Cardiomyopathy , HFrEF PAF Continued Eliquis, Atorvastatin, Metoprolol, corlanor  LVEF 30% in 2022  Given IV lasix, resume home PO lasix on discharge    CKD III  Cr stable 1.7 , bumped to 2.15  Bumped with IV Lasix DM II noninsulin dependent Diet controlled at home  A1c 11/6 6 Sliding scale insulin while on high dose steroids,  Cont home jardiance
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitus in my right ear
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: VACCINE GIVEN AFTER VIABILITY DATE
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: Acute kidney injury, Acute respiratory failure, Anaemia, Aspiration, Atrial fibrillation
Clinical narrative: Patient is an 87 year old  male with a history of Afib, mechanical MV,  Anemia, NSCLC, 3rd degree AV block s/p AICD, Heart Failure, CKD IV, who presented to Facility 10/31/23 with shock, hypoxic respiratory failure requiring ICU stay and transferred out of the ICU with improvement after finding COVID-19, Pseudomonas Pneumonia with course complicated with dysphagia and respiratory failure and decision made to pursue comfort care. He passed away on 11/13/23 at 0645.    1. End Of Life Care: secondary to dysphagia, cachexia, persistent respiratory failure. Palliative followed. Comfort medications provided.  2. Acute Respiratory Failure: Secondary to mucous plugging, pulmonary edema, pneumonia with COVID-19 and Pseudomonas. Repeat bronchoscopy on 11/4/23. Pulmonology followed. Given intolerance to BiPAP and worsening overall condition decision made to pursue comfort care. 3. COVID 19: Positive PCR from bronchial washings on 11/4/23.  Began on Remdesivir for 5 days ending 11/9/2023, s/p decadron.  4. Pseudomonas Pneumonia with Sepsis: sepsis now resolved, positive from bronch washings on 11/4/2023.  Began on Cefepime on 11/5/23, switched to IV Cipro 11/6/23 but stopped after transition to CC 11/8/23  5. AKI on CKD stage 4: Thought to be due to shock with baseline creatinine around 2-2.3. Comfort care.  6. Chronic Anemia: Hb stable in the 9s. Stopped trending CBC give goals of care. 7. Thrombocytopenia: likely reactive. Platelets 135k on 11/6/23.   8. Atrial Fibrillation: symptomatic care 9. Chronic Systolic Heart Failure: TTE on 11/1/23 with EF of 32%.  10. Dysphagia: MBS 11/8/23 with aspiration to all substances. Comfort care with comfort diet.    Patient passed away on 11/13/23 at 0645. Spoke with patient's grandson and chaplain met with patient's wife and grandson as well.
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: Blood creatinine increased, Bronchial secretion retention, Bronchoalveolar lavage, Bronchoscopy, COVID-19
Clinical narrative: Patient is an 87 year old  male with a history of Afib, mechanical MV,  Anemia, NSCLC, 3rd degree AV block s/p AICD, Heart Failure, CKD IV, who presented to Facility 10/31/23 with shock, hypoxic respiratory failure requiring ICU stay and transferred out of the ICU with improvement after finding COVID-19, Pseudomonas Pneumonia with course complicated with dysphagia and respiratory failure and decision made to pursue comfort care. He passed away on 11/13/23 at 0645.    1. End Of Life Care: secondary to dysphagia, cachexia, persistent respiratory failure. Palliative followed. Comfort medications provided.  2. Acute Respiratory Failure: Secondary to mucous plugging, pulmonary edema, pneumonia with COVID-19 and Pseudomonas. Repeat bronchoscopy on 11/4/23. Pulmonology followed. Given intolerance to BiPAP and worsening overall condition decision made to pursue comfort care. 3. COVID 19: Positive PCR from bronchial washings on 11/4/23.  Began on Remdesivir for 5 days ending 11/9/2023, s/p decadron.  4. Pseudomonas Pneumonia with Sepsis: sepsis now resolved, positive from bronch washings on 11/4/2023.  Began on Cefepime on 11/5/23, switched to IV Cipro 11/6/23 but stopped after transition to CC 11/8/23  5. AKI on CKD stage 4: Thought to be due to shock with baseline creatinine around 2-2.3. Comfort care.  6. Chronic Anemia: Hb stable in the 9s. Stopped trending CBC give goals of care. 7. Thrombocytopenia: likely reactive. Platelets 135k on 11/6/23.   8. Atrial Fibrillation: symptomatic care 9. Chronic Systolic Heart Failure: TTE on 11/1/23 with EF of 32%.  10. Dysphagia: MBS 11/8/23 with aspiration to all substances. Comfort care with comfort diet.    Patient passed away on 11/13/23 at 0645. Spoke with patient's grandson and chaplain met with patient's wife and grandson as well.
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19 pneumonia, Cachexia, Chronic left ventricular failure, Condition aggravated, Death
Clinical narrative: Patient is an 87 year old  male with a history of Afib, mechanical MV,  Anemia, NSCLC, 3rd degree AV block s/p AICD, Heart Failure, CKD IV, who presented to Facility 10/31/23 with shock, hypoxic respiratory failure requiring ICU stay and transferred out of the ICU with improvement after finding COVID-19, Pseudomonas Pneumonia with course complicated with dysphagia and respiratory failure and decision made to pursue comfort care. He passed away on 11/13/23 at 0645.    1. End Of Life Care: secondary to dysphagia, cachexia, persistent respiratory failure. Palliative followed. Comfort medications provided.  2. Acute Respiratory Failure: Secondary to mucous plugging, pulmonary edema, pneumonia with COVID-19 and Pseudomonas. Repeat bronchoscopy on 11/4/23. Pulmonology followed. Given intolerance to BiPAP and worsening overall condition decision made to pursue comfort care. 3. COVID 19: Positive PCR from bronchial washings on 11/4/23.  Began on Remdesivir for 5 days ending 11/9/2023, s/p decadron.  4. Pseudomonas Pneumonia with Sepsis: sepsis now resolved, positive from bronch washings on 11/4/2023.  Began on Cefepime on 11/5/23, switched to IV Cipro 11/6/23 but stopped after transition to CC 11/8/23  5. AKI on CKD stage 4: Thought to be due to shock with baseline creatinine around 2-2.3. Comfort care.  6. Chronic Anemia: Hb stable in the 9s. Stopped trending CBC give goals of care. 7. Thrombocytopenia: likely reactive. Platelets 135k on 11/6/23.   8. Atrial Fibrillation: symptomatic care 9. Chronic Systolic Heart Failure: TTE on 11/1/23 with EF of 32%.  10. Dysphagia: MBS 11/8/23 with aspiration to all substances. Comfort care with comfort diet.    Patient passed away on 11/13/23 at 0645. Spoke with patient's grandson and chaplain met with patient's wife and grandson as well.
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: Device intolerance, Dysphagia, Echocardiogram, Ejection fraction decreased, Full blood count
Clinical narrative: Patient is an 87 year old  male with a history of Afib, mechanical MV,  Anemia, NSCLC, 3rd degree AV block s/p AICD, Heart Failure, CKD IV, who presented to Facility 10/31/23 with shock, hypoxic respiratory failure requiring ICU stay and transferred out of the ICU with improvement after finding COVID-19, Pseudomonas Pneumonia with course complicated with dysphagia and respiratory failure and decision made to pursue comfort care. He passed away on 11/13/23 at 0645.    1. End Of Life Care: secondary to dysphagia, cachexia, persistent respiratory failure. Palliative followed. Comfort medications provided.  2. Acute Respiratory Failure: Secondary to mucous plugging, pulmonary edema, pneumonia with COVID-19 and Pseudomonas. Repeat bronchoscopy on 11/4/23. Pulmonology followed. Given intolerance to BiPAP and worsening overall condition decision made to pursue comfort care. 3. COVID 19: Positive PCR from bronchial washings on 11/4/23.  Began on Remdesivir for 5 days ending 11/9/2023, s/p decadron.  4. Pseudomonas Pneumonia with Sepsis: sepsis now resolved, positive from bronch washings on 11/4/2023.  Began on Cefepime on 11/5/23, switched to IV Cipro 11/6/23 but stopped after transition to CC 11/8/23  5. AKI on CKD stage 4: Thought to be due to shock with baseline creatinine around 2-2.3. Comfort care.  6. Chronic Anemia: Hb stable in the 9s. Stopped trending CBC give goals of care. 7. Thrombocytopenia: likely reactive. Platelets 135k on 11/6/23.   8. Atrial Fibrillation: symptomatic care 9. Chronic Systolic Heart Failure: TTE on 11/1/23 with EF of 32%.  10. Dysphagia: MBS 11/8/23 with aspiration to all substances. Comfort care with comfort diet.    Patient passed away on 11/13/23 at 0645. Spoke with patient's grandson and chaplain met with patient's wife and grandson as well.
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: General physical health deterioration, Haemoglobin decreased, Intensive care, Platelet count decreased, Pneumonia pseudomonal
Clinical narrative: Patient is an 87 year old  male with a history of Afib, mechanical MV,  Anemia, NSCLC, 3rd degree AV block s/p AICD, Heart Failure, CKD IV, who presented to Facility 10/31/23 with shock, hypoxic respiratory failure requiring ICU stay and transferred out of the ICU with improvement after finding COVID-19, Pseudomonas Pneumonia with course complicated with dysphagia and respiratory failure and decision made to pursue comfort care. He passed away on 11/13/23 at 0645.    1. End Of Life Care: secondary to dysphagia, cachexia, persistent respiratory failure. Palliative followed. Comfort medications provided.  2. Acute Respiratory Failure: Secondary to mucous plugging, pulmonary edema, pneumonia with COVID-19 and Pseudomonas. Repeat bronchoscopy on 11/4/23. Pulmonology followed. Given intolerance to BiPAP and worsening overall condition decision made to pursue comfort care. 3. COVID 19: Positive PCR from bronchial washings on 11/4/23.  Began on Remdesivir for 5 days ending 11/9/2023, s/p decadron.  4. Pseudomonas Pneumonia with Sepsis: sepsis now resolved, positive from bronch washings on 11/4/2023.  Began on Cefepime on 11/5/23, switched to IV Cipro 11/6/23 but stopped after transition to CC 11/8/23  5. AKI on CKD stage 4: Thought to be due to shock with baseline creatinine around 2-2.3. Comfort care.  6. Chronic Anemia: Hb stable in the 9s. Stopped trending CBC give goals of care. 7. Thrombocytopenia: likely reactive. Platelets 135k on 11/6/23.   8. Atrial Fibrillation: symptomatic care 9. Chronic Systolic Heart Failure: TTE on 11/1/23 with EF of 32%.  10. Dysphagia: MBS 11/8/23 with aspiration to all substances. Comfort care with comfort diet.    Patient passed away on 11/13/23 at 0645. Spoke with patient's grandson and chaplain met with patient's wife and grandson as well.